Pig Improvement Company (PIC) - North America: Company Profile

Background

Pig Improvement Company (PIC) is a leading provider of swine genetics, dedicated to enhancing the success of pork producers worldwide. Established in 1962 in Oxfordshire, England, PIC has grown to operate in over 40 countries, offering genetically superior breeding stock and comprehensive technical services. As a subsidiary of Genus plc, a UK-based company specializing in animal genetics, PIC's mission is to pioneer animal genetic improvement to help nourish the world.

Key Strategic Focus

PIC's strategic focus centers on delivering high-quality swine genetics that drive profitability for pork producers. The company emphasizes:

Genetic Improvement: Applying advanced science to enhance pig performance by selecting commercially relevant traits and developing technologies to accelerate genetic gain.

Global Supply Chain: Maintaining a biosecure supply system to deliver world-renowned genetics efficiently.

Customer Support: Providing on-farm experts to help producers realize the full value of PIC genetics.

Financials and Funding

PIC operates as a subsidiary of Genus plc, a publicly traded company on the London Stock Exchange. Specific financial details for PIC North America are not publicly disclosed. However, estimates suggest that PIC North America generates approximately $79 million in annual revenue, with around 510 employees.

Pipeline Development

PIC has been at the forefront of genetic advancements in swine production, notably developing PRRS-resistant pigs. In February 2026, Canadian regulators approved PIC's PRRS-resistant pigs for sale as food, marking a significant milestone in combating Porcine Reproductive and Respiratory Syndrome (PRRS).

Technological Platform and Innovation

PIC leverages several technological platforms and innovations:

Genetic Nucleus (APEX): A new genetic nucleus developed in 2009 to enhance genetic improvement.

PICTraq™: Introduced in 1998, this system aids in data capture and analysis for improved selection accuracy.

Gene-Edited Pigs: PIC has developed gene-edited pigs resistant to PRRS, with approvals in multiple countries, including the U.S. and Canada.

Leadership Team

PIC's leadership team includes:

Matt Culbertson: Chief Operating Officer, overseeing operations and strategic initiatives.

Paul Van Der Meijden: General Manager, responsible for managing daily operations.

Jan Welvaarts: Technical Director, leading technical services and product development.

Competitor Profile

Market Insights and Dynamics

The swine genetics industry is characterized by a focus on improving pig health, productivity, and profitability. Advancements in genetic research, such as disease-resistant breeds, are pivotal in addressing challenges like PRRS.

Competitor Analysis

Key competitors in the swine genetics sector include:

Swine Innovation Porc: A Canadian organization focused on research and development within the swine sector.

Pipestone: Provides services in health, management, nutrition, research, and business support for pig farmers.

Cobra Biologics: A contract development and manufacturing organization specializing in the biotechnology sector.

Strategic Collaborations and Partnerships

In November 2022, PIC made a strategic minority investment in SwineTech, a farm management solutions company. This partnership aims to develop innovative products and approaches to improve the predictability and efficiency of swine production.

Operational Insights

PIC's global biosecure supply system and commitment to genetic improvement position it as a leader in the swine genetics industry. The company's focus on customer support and technological innovation provides a competitive edge in delivering value to pork producers.

Strategic Opportunities and Future Directions

PIC's development of PRRS-resistant pigs opens new markets and opportunities for expansion. The company's ongoing investment in genetic research and strategic partnerships positions it to address global challenges in swine production and enhance its market presence.